New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
10:49 EDTEGRXEagle Pharmaceuticals price target raised to $30 from $22 at Cantor
Cantor said Ryanodex, which Eagle Pharmaceuticals has priced significantly above the firm's initial expectations, is planned to launch at the end of this month and should help offset some of the losses associated with argatroban. The firm raised its price target on Eagle to $30 from $22 and reiterates its Buy rating on the shares.
News For EGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
06:41 EDTEGRXEagle Pharmaceuticals price target raised to $94 from $75 at Piper Jaffray
Subscribe for More Information
July 2, 2015
13:19 EDTEGRXCantor lowers sales assumptions for Eagle's Angiomax version
After an appeals court invalidated the Angiomax patents held by The Medicines Company (MDCO), Cantor Fitzgerald lowered its price target for Eagle Pharmaceuticals (EGRX) to $92 from $95 to reflect more modest sales assumptions for the company's version of Angiomax. Cantor had previously modeled a more favorable for Eagle whereby there were no generic entrants until 2019. The firm, however, still sees the stock as undervalued and keeps a Buy rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use